13.09.2017 08:59

Sophia Genetics raises $30 million

The company will use the resources to further develop its cutting-edge technology. Additionally, the company will continue recruiting top talent and accelerate hospitals’ adoption of clinical genomics testing.


12.09.2017 10:57

Kenzen: Combining US sales culture with Swiss technology

Kenzen, an innovator of wearables for precision health, has two headquarters in San Francisco and Switzerland. The combination works well, the start-up raised $5 million from strategic investors. The team in Switzerland will now be expanded. 


08.09.2017 13:29

16 Start-ups selected for the Swiss Venture Day Romandie

Swiss Startup Invest has completely redesigned its Swiss Venture Day to allow for one to one meetings, keynote speeches and startup pitches. The first Venture Day Romandie in the new format will take place on 19 September. More than 130 people have already registered.


06.09.2017 15:55

Venture capital firms expand investment offer for startups

Two venture capital firms announced the extension of their investment offering for startups. The Swiss listed investment firm 5EL SA has already added blockchain business unit “5EL Blockchain Lab” while Polytech Ecosystems Ventures is currently soliciting CHF 100 million for its future investments for Swiss and European hightech startups.

06.09.2017 08:13

Online-Suchdienst übernimmt Ö SA kündigt die Akquisition des Informationsportals Ö der AG an. Mit mehr als 25‘000 registrierten Geschäftsstellen und über 300‘000 Besuchen pro Monat ist Ö die meist frequentierte Webseite zum Thema „Öffnungszeiten“ in der Schweiz.


05.09.2017 16:37 raises $10 million in token sale in five hours announces that its token sale has raised $10 million in only five hours of opening on Friday 1 September, successfully fundraising for its revolutionary product using Blockchain and IoT technology in the pharma supply chain. The MOD token sale will be used to bring’s innovative supply chain solution to the market.

05.09.2017 11:45

AMAL Therapeutics raises CHF 8.8 million in Series B round

AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, announces today that it has completed the first tranche of its Series B financing round, raising of Euros 8 million (CHF 8.8 million). AMAL will use the funds to progress its lead vaccine and further develop its proprietary therapeutic tumour vaccination technology platform called KISIMA.

Show All


Unfortunately, no events were found matching the given criteria!

Show All


27.09.2017 16:45 - 19:00

Innovations-Chat Startfeld Innovationszentrum, Lerchenfeldstrasse 3, 9014 St.Gallen

Top viewed

Show All




ZKB Pionierpreis Technopark: Deadline approaching

Deadline for ZKB Pionierpreis Technopark is on 25 September. Do not miss it!